These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 7309892)

  • 21. [Modifications of peptide hydroxyprolinuria during Paget's disease and osteoma (author's transl)].
    Dakkak R; Goussault Y; Dreux C
    Ann Biol Clin (Paris); 1979; 37(4):195-200. PubMed ID: 525849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chromatographic analysis of urinary amino acids in Paget's disease. I : Biochemical study. Isolation and amino acid composition of a urinary peptide specific to this bone disease].
    Fabier JL; Viau M; Constans J; Clerc A
    Rev Rhum Mal Osteoartic; 1976 Apr; 43(4):249-53. PubMed ID: 1273474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycosaminoglycan excretion in osteogenesis imperfecta.
    Hurst RE; Settine JM; Floyd WM; Lorincz AE
    Clin Chim Acta; 1980 Jan; 100(3):307-11. PubMed ID: 7353313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases.
    Stĕpán J; Pacovský V; Horn V; Silinková-Málková E; Vokrouhlická O; Konopásek B; Formánková J; Hrba J; Marek J
    Eur J Clin Invest; 1978 Dec; 8(6):373-7. PubMed ID: 105909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of the urinary hydroxyproline level in the screening for collagen diseases].
    Gambella GR; Zunino M
    Minerva Med; 1986 Apr; 77(16):607-12. PubMed ID: 3703359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of sex, height and time of day on the excretion of glycosaminoglycans and the consequences.
    Poulsen JH; Vaeth M
    Scand J Clin Lab Invest; 1982 Feb; 42(1):41-7. PubMed ID: 6890231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Determination of serum proline iminopeptidase activity using a fluorescent substrate in patients with Paget's disease and prostatic bone metastases. Preliminary results].
    Bouvier M; Colson F; Tebib J; Mathieu M; Vianey-Liaud C
    Pathol Biol (Paris); 1986 Apr; 34(4):235-9. PubMed ID: 3528996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation.
    Krane SM; Kantrowitz FG; Byrne M; Pinnell SR; Singer FR
    J Clin Invest; 1977 May; 59(5):819-27. PubMed ID: 404321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low serum magnesium concentration in Paget's disease of bone (osteitis deformans).
    Taylor WH
    Ann Clin Biochem; 1985 Nov; 22 ( Pt 6)():591-5. PubMed ID: 4073791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.
    Uebelhart D; Gineyts E; Chapuy MC; Delmas PD
    Bone Miner; 1990 Jan; 8(1):87-96. PubMed ID: 2106358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Paget's osteodystrophia deformans. Occurrence, clinical aspects and complications].
    Ringe JD; Kuhlencordt F
    Dtsch Med Wochenschr; 1979 Dec; 104(52):1837-42. PubMed ID: 520181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone.
    Bockman RS; Wilhelm F; Siris E; Singer F; Chausmer A; Bitton R; Kotler J; Bosco BJ; Eyre DR; Levenson D
    J Clin Endocrinol Metab; 1995 Feb; 80(2):595-602. PubMed ID: 7852526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcitonin nasal spray for Paget's disease of the bone].
    Luboshitzky R; Bar-Shalom R
    Harefuah; 1995 Mar; 128(6):358-62, 399. PubMed ID: 7750816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
    Torres R; de la Piedra C; Rapado A
    Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in connective tissue metabolism due to bone fractures in children aged 10--14 years. I. Urinary hydroxyproline and glycosaminoglycan excretion during fracture repair.
    Kustos G
    Acta Chir Acad Sci Hung; 1979; 20(1):69-78. PubMed ID: 554381
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evaluation of clinical and humoral data in 148 patients with Piaget's bone disease].
    Fromm GA; Roca JF; Mautalén CA; Casco C
    Medicina (B Aires); 1980; 40(6 Pt 1):635-42. PubMed ID: 22167694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of hydroxyproline polypeptides in urine and blood serum by gel filtration.
    Dubovsky J; Meyer RD
    Clin Chim Acta; 1975 Jul; 62(2):277-86. PubMed ID: 1097133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormal vitamin D metabolism in Paget's disease of bone.
    Guillard-Cumming DF; Beard DJ; Douglas DL; Johnson SK; Lawson-Matthew PJ; Russell RG; Kanis JA
    Clin Endocrinol (Oxf); 1985 Apr; 22(4):559-66. PubMed ID: 3872746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.
    Robins SP; Black D; Paterson CR; Reid DM; Duncan A; Seibel MJ
    Eur J Clin Invest; 1991 Jun; 21(3):310-5. PubMed ID: 1909635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.